ASCO 2020: The shifting paradigm in drug development: from tissue specific to tumour-agnostic

3 June 2020 (Last Updated June 3rd, 2020 12:46)

Clinical ontology development has traditionally targeted cancer-dependent target identification; over the past two decades, a number of therapeutic modalities have been designed to target a vast array of molecular signatures in cancer. Elucidation of the genetic landscape of tissue-specific cancers allowed the establishment of mutation-specific targeted treatments, allowing realistic aspiration for targeted therapies customised to the particular genetic aberrations found in a patient's tumour.

Earlier this year at ASCO 2020 exposed a shift away from this paradigm, particularly for targeting rare cancers, from tissue-specific to tissue-agnostic drug development. Read more here.